secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001104659-26-000620
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront
----------------------------------------------------------------------------

- Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.
- Genentech pays $100M one-time non-refundable fee within 30 days; plus low single-digit royalties.
- License covers patents distinct from aleniglipron; Structure's own GLP-1/dual agonist programs unaffected.
- Either party may terminate for uncured material breach; Gasherbrum can terminate if GNE challenges patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/0001104659-26-000620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/tm261919d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-000620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer